CADTH Canadian Drug Expert Committee final recommendation. indication: moderate to severe plaque psoriasis. Ixekizumab (Taltz -- Eli Lilly Canada Inc.) :

Similar Items

• CADTH Canadian Drug Expert Committee recommendation. Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity.
  Published: (2018)
• CADTH Canadian Drug Expert Committee final recommendation. Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma.
  Published: (2016)
• CADTH Canadian Drug Expert Committee recommendation. Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis.
  Published: (2018)
• CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
  Published: (2018)
• CADTH Canadian Drug Expert Committee recommendation. Ivabradine hydrochloride (Lancora -- Servier Canada Inc.) : indication: heart failure, NYHA class II to III.
  Published: (2017)